ERBB2 and breast carcinoma: Previous studies have shown that trastuzumab, whether as a single drug or in combination with chemotherapy, can delay the disease progression and improve the OS of breast cancer patients with human epidermal growth factor receptor 2 (HER-2) positivity (Kak et al., 2015; Malani et al., 2020).